Agents Used in Antiretroviral Therapy
Summary
- Entry inhibitors block binding of gp120 to CD4 receptors
- Currently only 1 FDA-approved CCR5 antagonist is available: maraviroc (Table 11)
- Ibalizumab-uiyk prevents the interaction of gp 120 with CCR5 and CXCR4 and is approved for use in heavily treatment–experienced patients with multidrug-resistant HIV Ibalizumab
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content